LitAlert ~~ GeneLit.com

    • Impact of BRCA Status on Reproductive Decision-Making and Self-Concept: A Mixed-Methods Study Informing the Development of Tailored Interventions.
    • Hesse-Biber S, Seven M, Jiang J, Van Schaik S, Dwyer AA.
    • Cancers (Basel). 2022 Mar 15;14(6):1494. doi: 10.3390/cancers14061494.
    • Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes.
    • Kohaar I, Zhang X, Tan SH, Nousome D, Babcock K, Ravindranath L, Sukumar G, Mcgrath-Martinez E, Rosenberger J, Alba C, Ali A, Young S, Chen Y, Cullen J, Rosner IL, Sesterhenn IA, Dobi A, Chesnut G, Turner C, Dalgard C, Wilkerson MD, Pollard HB, Srivastava S, Petrovics G.
    • Nat Commun. 2022 Mar 15;13(1):1361. doi: 10.1038/s41467-022-28945-x.
    • Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
    • Lieberman S, Goldvaser H, Levy-Lahad E.
    • J Clin Oncol. 2022 Mar 14:JCO2200003. doi: 10.1200/JCO.22.00003. Epub ahead of print.
    • Commentary

    Original research:

    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.

    • Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
    • Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM.
    • Lancet Oncol. 2022 Mar 14:S1470-2045(22)00122-X. doi: 10.1016/S1470-2045(22)00122-X. Epub ahead of print.

    Commentary:

    Rucaparib for BRCA1/2-mutated pretreated ovarian cancer: reflections from the ARIEL4 trial.

    • FDA Approves First PARP Inhibitor for Early BRCA+ Breast Cancer.
    • Worcester S.
    • Medscape. Oncology. 2022 Mar 14.

    Press Release: FDA Approves LYNPARZA® (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBRCAm), HER2-Negative High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvant Chemotherapy. (Merck)

    Press Release: Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer. (Myriad Genetics)

    • Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2.
    • Sangree AK, Griffith AL, Szegletes ZM, Roy P, DeWeirdt PC, Hegde M, McGee AV, Hanna RE, Doench JG.
    • Nat Commun. 2022 Mar 14;13(1):1318. doi: 10.1038/s41467-022-28884-7.
    • Transforming the 2-week wait (2WW) pathway: management of breast pain in primary care.
    • Jahan M, Bartholomeuz T, Milburn N, Rogers V, Sibbering M, Robertson J.
    • BMJ Open Qual. 2022 Mar;11(1):e001634. doi: 10.1136/bmjoq-2021-001634.